BioSig Allowed Additional Foundational US Patent for its PURE EP(tm) System
August 01 2019 - 9:00AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical
device company developing a proprietary biomedical signal
processing platform designed to address an unmet technology need
for the electrophysiology (EP) marketplace, today announced that
the US Patent Office has allowed another foundational patent
including additional 29 patent claims covering its PURE EPTM
System. The patent application number 16/271,466 entitled "Systems
and Methods for Signal Acquisition and Visualization," was filed on
May 9, 2018 and subject to an accelerated Track One patent
application filed on February 8, 2019. The patent has not yet
been published. The allowed claims provide even broader patent
coverage for the company’s PURE EPTM System and address the overall
system architecture for filtering biomedical signals during a
medical procedure such as an ablation procedure in frequency ranges
of interest to the practitioner. The allowed claims address the
novel system architecture related to a unique amplifier topology
for conditioning cardiac (e.g., ECG and intra-cardiac) and other
physiologic signals, specifically to clearly define and record
low-amplitude, frequency-specific information, which may be
acquired during ablation and other large-signal perturbations, such
as pacing. This ensures the acquisition of multiple low amplitude
cardiac signals in the presence of numerous sources of electrical
noise and environmental interference aside from the large signals
injected during ablation and pacing.
“We are pleased that the US Patent Office continues to quickly
recognize the novelty of our advanced PURE EPTM System and to
receive further patent protection for our proprietary
technology. BioSig continues to expand its intellectual
property estate with three recent patent allowances including this
one, and we are pleased to add this additional patent to our
growing intellectual property portfolio covering our PURE EPTM
System,” stated Kenneth L. Londoner, Founder, Chairman and CEO of
BioSig Technologies, Inc.
The PURE EPTM System is indicated as a computerized system
intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory
under the supervision of licensed healthcare practitioners who are
responsible for interpreting the data.
About BioSig TechnologiesBioSig Technologies is
a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EPTM System.
The technology has been developed to address an unmet need in a
large and growing market.
The Company’s first product, PURE EPTM System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory.
The system is indicated for use under the supervision of licensed
healthcare practitioners who are responsible for interpreting the
data. This novel cardiac signal acquisition and display system is
engineered to assist electrophysiologists in clinical
decision-making during electrophysiology procedures in patients
with abnormal heart rates and rhythms. BioSig’s ultimate goal is to
deliver technology to improve upon catheter ablation treatments for
the prevalent and potentially deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with
Minnetronix on technology development and received FDA 510(k)
clearance for the PURE EP(tm) System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024